Form SC 13G - Statement of acquisition of beneficial ownership by individuals
13 Februar 2024 - 11:11PM
Edgar (US Regulatory)
Securities and Exchange Commission
Washington, D.C. 20549
Schedule 13G
(Rule 13d-102)
Information to be Included in Statements Filed Pursuant
to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed
Pursuant to § 240.13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
AN2 Therapeutics, Inc.
(Name of Issuer)
Common
Stock
(Title of Class of Securities)
037326105
(CUSIP Number)
December 31, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| * |
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of
the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
| CUSIP No. 037326105 |
|
Schedule 13G |
|
Page 1 of 5 |
|
|
|
|
|
|
|
| 1 |
|
Names of Reporting Persons
Eric Easom |
| 2 |
|
Check the Appropriate Box if a
Member of a Group
(a) ☐ (b) ☐ |
| 3 |
|
SEC Use Only
|
| 4 |
|
Citizenship or Place of
Organization United
States |
|
|
|
|
|
|
|
| Number of
Shares
Beneficially
Owned by Each
Reporting Person
With |
|
5 |
|
Sole Voting Power
1,572,170 |
| |
6 |
|
Shared Voting Power
0 |
| |
7 |
|
Sole Dispositive Power
1,572,170 |
| |
8 |
|
Shared Dispositive Power
0 |
|
|
|
|
|
|
|
| 9 |
|
Aggregate Amount Beneficially Owned by Each Reporting Person
1,572,170 |
| 10 |
|
Check if the Aggregate Amount
in Row (9) Excludes Certain Shares Not Applicable |
| 11 |
|
Percent of
Class Represented by Amount in Row 9 5.2% |
| 12 |
|
Type of Reporting Person
IN |
|
|
|
|
|
| CUSIP No. 037326105 |
|
Schedule 13G |
|
Page 2 of 5 |
| ITEM 1. |
(a) Name of Issuer: |
AN2 Therapeutics, Inc. (the “Issuer”).
| |
(b) |
Address of Issuer’s Principal Executive Offices: |
1800 El Camino Real, Suite D, Menlo Park, CA 94027
| ITEM 2. |
(a) Name of Person Filing: |
This statement is filed on behalf of Eric Easom (the “Reporting Person”).
| |
(b) |
Address or Principal Business Office: |
The business address of the Reporting Person is c/o AN2 Therapeutics, Inc., 1800 El Camino Real, Suite D, Menlo Park, CA
94027.
| |
(c) |
Citizenship of each Reporting Person is: |
The Reporting Person is a citizen of the United States.
| |
(d) |
Title of Class of Securities: |
Common Stock, par value $0.00001 per share (“Common Stock”).
037326105
Not applicable.
|
|
|
|
|
| CUSIP No. 037326105 |
|
Schedule 13G |
|
Page 3 of 5 |
(a-c)
The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31,
2023, based upon 29,741,445 shares of Common Stock outstanding as of November 2, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on
November 9, 2023.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reporting Person |
|
Amount
beneficially
owned |
|
|
Percent
of class: |
|
|
Sole power
to vote or
to direct
the vote: |
|
|
Shared power
to vote or to
direct the vote: |
|
|
Sole
power to
dispose or
to direct
the
disposition
of: |
|
|
Shared
power to dispose or
to direct the
disposition
of: |
|
| Eric Easom |
|
|
1,572,170 |
|
|
|
5.2 |
% |
|
|
1,572,170 |
|
|
|
0 |
|
|
|
1,572,170 |
|
|
|
0 |
|
The Reporting Person is the beneficial owner of 1,572,170 shares of Common Stock, which
consists of (i) 4,907 shares of Common Stock held directly by the Reporting Person, (ii) 1,209,882 shares of Common Stock held by various family trusts, over which the Reporting Person serves as trustee, and (iii) 357,381 shares of Common Stock
underlying stock options that are vested or will vest within 60 days of December 31, 2023.
| ITEM 5. |
Ownership of Five Percent or Less of a Class. |
Not applicable.
| ITEM 6. |
Ownership of More than Five Percent on Behalf of Another Person. |
Not applicable.
| ITEM 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the
Parent Holding Company. |
Not applicable.
| ITEM 8. |
Identification and Classification of Members of the Group. |
Not applicable.
| ITEM 9. |
Notice of Dissolution of Group. |
Not applicable.
|
|
|
|
|
| CUSIP No. 037326105 |
|
Schedule 13G |
|
Page 4 of 5 |
Not applicable.
|
|
|
|
|
| CUSIP No. 037326105 |
|
Schedule 13G |
|
Page 5 of 5 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: February 13, 2024
|
| Eric Easom |
| /s/ Eric Easom |
AN2 Therapeutics (NASDAQ:ANTX)
Historical Stock Chart
Von Dez 2024 bis Dez 2024
AN2 Therapeutics (NASDAQ:ANTX)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
